Vertex Pharmaceuticals (VRTX) Interest Expenses (2009 - 2026)

Vertex Pharmaceuticals' Interest Expenses history runs 18 years deep, the most recent figure standing at $420.3 million for Q1 2026.

• On a quarterly basis, Interest Expenses rose 17.6% year-over-year to $420.3 million in Q1 2026; TTM through Mar 2026 was $420.3 million, a 17.6% increase from a year earlier, with the FY2025 full-year figure at $436.6 million, up 27.89% from the prior year.
• Interest Expenses climbed to $420.3 million in Q1 2026 per VRTX's latest filing, from $3.9 million in the prior quarter.
• Across five years, Interest Expenses topped out at $2.8 billion in Q3 2024 and bottomed at $3.9 million in Q4 2025.
• The 5-year median for Interest Expenses is $245.4 million (2023), against an average of $369.6 million.
• Across the five-year window, Interest Expenses jumped 1038.88% in 2024 and tumbled 95.45% in 2025, its largest moves.
• Year by year, Interest Expenses stood at $11.2 million in 2022, then fell by 5.36% to $10.6 million in 2023, then jumped by 708.49% to $85.7 million in 2024, then tumbled by 95.45% to $3.9 million in 2025, then soared by 10676.92% to $420.3 million in 2026.
• Per Business Quant, the three latest VRTX Interest Expenses figures stand at $420.3 million (Q1 2026), $3.9 million (Q4 2025), and $421.6 million (Q3 2025).